Maureen R. Bleam

1.4k total citations
13 papers, 1.1k citations indexed

About

Maureen R. Bleam is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Maureen R. Bleam has authored 13 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Hematology. Recurrent topics in Maureen R. Bleam's work include Melanoma and MAPK Pathways (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Maureen R. Bleam is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Maureen R. Bleam collaborates with scholars based in United States, Germany and United Kingdom. Maureen R. Bleam's co-authors include Sylvie Laquerre, Aidan G. Gilmartin, Katherine G. Moss, Jingsong Yang, David Sutton, Symon G. Erskine, Kimberly N. Smitheman, Arthur Groy, Kelly E. Fisher and Roland S. Annan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Maureen R. Bleam

11 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maureen R. Bleam United States 6 862 548 189 166 154 13 1.1k
Aidan G. Gilmartin United States 12 902 1.0× 544 1.0× 244 1.3× 89 0.5× 119 0.8× 28 1.2k
Jahan Hussain United Kingdom 3 1.0k 1.2× 609 1.1× 118 0.6× 227 1.4× 203 1.3× 3 1.2k
Madhavi Tadi United States 7 849 1.0× 429 0.8× 83 0.4× 138 0.8× 175 1.1× 7 1.0k
Arturo Galvani Italy 21 689 0.8× 418 0.8× 161 0.9× 80 0.5× 105 0.7× 55 1.2k
Allison Marlow United States 3 724 0.8× 447 0.8× 62 0.3× 98 0.6× 166 1.1× 3 946
Charles Ng United States 10 962 1.1× 658 1.2× 82 0.4× 195 1.2× 177 1.1× 11 1.2k
Patrícia Volpe United States 4 963 1.1× 639 1.2× 131 0.7× 108 0.7× 157 1.0× 6 1.3k
Christian Haslinger Austria 9 775 0.9× 308 0.6× 231 1.2× 50 0.3× 113 0.7× 15 1.1k
Tammie C. Yeh United States 11 614 0.7× 503 0.9× 86 0.5× 56 0.3× 115 0.7× 21 1.0k
Meghna Das Thakur United States 14 820 1.0× 580 1.1× 288 1.5× 101 0.6× 118 0.8× 28 1.3k

Countries citing papers authored by Maureen R. Bleam

Since Specialization
Citations

This map shows the geographic impact of Maureen R. Bleam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maureen R. Bleam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maureen R. Bleam more than expected).

Fields of papers citing papers by Maureen R. Bleam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maureen R. Bleam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maureen R. Bleam. The network helps show where Maureen R. Bleam may publish in the future.

Co-authorship network of co-authors of Maureen R. Bleam

This figure shows the co-authorship network connecting the top 25 collaborators of Maureen R. Bleam. A scholar is included among the top collaborators of Maureen R. Bleam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maureen R. Bleam. Maureen R. Bleam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
3.
Im, Annie, Daniel Wolff, Corey Cutler, et al.. (2022). Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309. Blood. 140(Supplement 1). 1870–1871. 5 indexed citations
4.
Im, Annie, Rodica Morariu-Zamfir, Maureen R. Bleam, Ying Yan, & Steven Z. Pavletic. (2019). Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309). Blood. 134(Supplement_1). 3277–3277. 5 indexed citations
5.
Forero‐Torres, Andres, M. S. Wertheim, Tycel Phillips, et al.. (2016). Abstract CT056: Preliminary safety, efficacy, and pharmacodynamics of a highly selective PI3Kδ inhibitor, INCB050465, in patients with previously treated B-cell malignancies. Cancer Research. 76(14_Supplement). CT056–CT056. 2 indexed citations
6.
7.
Liu, Li, Hong Shi, Maureen R. Bleam, et al.. (2014). Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.. Journal of Clinical Oncology. 32(15_suppl). 3513–3513. 4 indexed citations
8.
King, Alastair J., Marc R. Arnone, Maureen R. Bleam, et al.. (2013). Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE. 8(7). e67583–e67583. 163 indexed citations
9.
Corcoran, Ryan B., Gerald S. Falchook, Jeffrey R. Infante, et al.. (2013). Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).. Journal of Clinical Oncology. 31(15_suppl). 3507–3507. 11 indexed citations
10.
Greger, James, Stephen D. Eastman, Vivian Zhang, et al.. (2012). Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations. Molecular Cancer Therapeutics. 11(4). 909–920. 260 indexed citations
11.
Gilmartin, Aidan G., Maureen R. Bleam, Arthur Groy, et al.. (2011). GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clinical Cancer Research. 17(5). 989–1000. 459 indexed citations
12.
Degenhardt, Yan, Joel Greshock, Sylvie Laquerre, et al.. (2010). Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability. Molecular Cancer Therapeutics. 9(7). 2079–2089. 73 indexed citations
13.
Gilmartin, Aidan G., Maureen R. Bleam, Mark C. Richter, et al.. (2009). Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis. Cancer Research. 69(17). 6969–6977. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aidan G. Gilmartin Breakdown of academic impact, for papers by Jahan Hussain Breakdown of academic impact, for papers by Madhavi Tadi Breakdown of academic impact, for papers by Arturo Galvani Breakdown of academic impact, for papers by Allison Marlow Breakdown of academic impact, for papers by Charles Ng Breakdown of academic impact, for papers by Patrícia Volpe Breakdown of academic impact, for papers by Christian Haslinger Breakdown of academic impact, for papers by Tammie C. Yeh Breakdown of academic impact, for papers by Meghna Das Thakur
Rankless by CCL
2026